Asset Details
Do you wish to reserve the book?
Bioprocess Engineering of Induced Pluripotent Stem Cells for Application in Cell Therapy and Pre-Clinical Research
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Bioprocess Engineering of Induced Pluripotent Stem Cells for Application in Cell Therapy and Pre-Clinical Research
Do you wish to request the book?
Bioprocess Engineering of Induced Pluripotent Stem Cells for Application in Cell Therapy and Pre-Clinical Research
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Dissertation
Bioprocess Engineering of Induced Pluripotent Stem Cells for Application in Cell Therapy and Pre-Clinical Research
2014
Overview
The production of cardiomyocytes (CMs) from induced pluripotent stem cells (iPSCs) presents great potential for patient-specific regenerative therapies and cardiotoxicity drug evaluation. The successful translation of iPSCs to these fields requires the development of robust bioprocesses capable of producing CMs in high quality, quantity and purity. Traditional protocols for CM differentiation of iPSCs lack control and robustness and are thus inefficient. Furthermore, efficient cryopreservation and hypothermic storage strategies are a demand, as cell banking and transport is a prerequisite for clinical and industrial applications. The main aim of this thesis was the evaluation of different bioreactor systems for the production and purification of miPSC-derived CMs. Novel strategies for CM cryopreservation were tested. Also, CMs were used to study the cardioprotective effect of antioxidant compounds.The wave bioreactor was the most suitable system for CM differentiation, allowing high differentiation yields (60 CMs/input of miPSC) and the production of clinically relevant numbers of CMs (2.3x109 CMs), simultaneously reducing bioprocess duration when compared to stirred tank bioreactors. Produced CMs presented typical structural and functional features. Moreover, CryoStorTMCS10 and FBS+10%DMSO (with ROCKi pretreatment) revealed to be suitable solutions for cryopreservation of miPSC-derived CMs, achieving high cell recoveries after thawing. In addition, HypoThermosol®-FRS enabled hypothermic storage of CMs for up to 7 days. Finally, it was shown that CMs derived from miPSCs present potential to be used in the development of cardioprotective assays.This work demonstrates the establishment of a fully integrated bioprocess, capable of producing high quality miPSC-derived CMs in environmentally controlled bioreactors and ensuring efficient cryopreservation and storage of the produced cells. Hopefully, the knowledge acquired with this work can be translated to human iPSCs, presenting a relevant step forward towards the application of human CMs to clinical and industrial applications, such as cardiac regeneration, disease modeling and cardiotoxicity and cardioprotective cellbased assays.
